• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sofosbuvir plus ledipasvir may be effective in chronic HCV after viral relapse

byKenan Celtik, MSandSai Folmsbee
November 3, 2014
in Chronic Disease, Gastroenterology, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Sofosbuvir plus ledipasvir was effective in treating chronic hepatitis C virus (HCV) genotype 1 infection in patients who were not candidates for interferon and who suffered viral relapse after prior sofosbuvir-based treatment.

Evidence Rating Level: 2 (Good)

Study Rundown: Sofosbuvir, an NS5B inhibitor, is an alternative to interferon-based treatments for chronic hepatitis C virus (HCV) genotype 1 infections in patients who are not candidates for interferon, such as those with advanced liver disease. In the NIAID SPARE trial, some patients with viral relapse agreed to retreatment with daily oral sofosbuvir and ledipasvir. Ledipasvir is an NS5A inhibitor which may be effective against sofosbuvir-resistant S282T mutant HCV. The 14 patients enrolled had high baseline viral RNA loads, and half had advanced liver disease (one was infected with S282T HCV). By the 4th week of treatment with sofosbuvir plus ledipasvir, all patients were aviremic based on unquantifiable HCV RNA levels. There were no significant changes in hemoglobin levels or renal variables, with the exception of a patient with baseline grade 2 renal insufficiency who had a grade 3 event after taking amoxicillin for a dental procedure. All patients completed treatment, with only mild adverse events. Ultimately, this study is limited by its small sample size and lack of controls, but sofosbuvir plus ledipasvir shows promise for the treatment of chronic HCV genotype 1 infections in patients who are not candidates for interferon and suffer viral relapse after prior sofosbuvir-based treatment.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

In-Depth [prospective cohort]: This study included 14 patients who relapsed after treatment with sofosbuvir plus ribavirin for chronic HCV genotype 1 infection, with combined daily oral doses of sofosbuvir and ledipasvir. The average age of the patients was 59 years, 93% were black, 93% were men, median BMI was 28.5, and 50% had advanced liver disease. The baseline HCV RNA levels were high (median 6.31 log IU/ml), with 11% having very high HCV RNA levels >800,000 log IU/ml and one patient had S282T HCV infection. By the 4th week, all patients had HCV RNA levels below the quantifiable limit, maintained through the 12th week of treatment and at 12 weeks after the completion of treatment. There were no serious adverse events and all patients completed treatment.

Image: PD

RELATED REPORTS

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: hepatitis CLedipasvirsofosbuvir
Previous Post

2 Minute Medicine Rewind October 26 – November 2, 2014

Next Post

Atrial fibrillation likely increases risk of silent strokes

RelatedReports

Screening insufficient for newborns exposed to hepatitis C virus
Chronic Disease

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

July 26, 2022
Large spike in drug use-associated infective endocarditis linked with opioid epidemic
Gastroenterology

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

March 17, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

November 1, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

February 10, 2021
Next Post
Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

Atrial fibrillation likely increases risk of silent strokes

Patients at long-term increased mortality risk following stroke at young age

Dabigatran linked with more major bleeds, fewer intracranial hemorrhages vs warfarin

Physician disapproval of current maintenance of certification programs prevalent

Physician disapproval of current maintenance of certification programs prevalent

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Synergistic interaction between risk burden and genetics for atrial fibrillation development
  • Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
  • Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options